Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature

<table>Flow cytometric analysis of IGF-1R-PE-labeled ES and NWTb3 cells. Black: unlabeled cells; Red: IGF-1R-PE-labeled cells.</table>

Sarcoma

fig2

Figure 2

Figure 2: Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature 

Figure 2 | Insulin-Like Growth Factor 1 Receptor as a Therapeutic Target in Ewing Sarcoma: Lack of Consistent Upregulation or Recurrent Mutation and a Review of the Clinical Trial Literature 